Vaccinex Inc (VCNX)

OTC Markets
Currency in USD
0.710
-0.110(-13.41%)
Delayed Data·
VCNX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VCNX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.7100.720
52 wk Range
0.2528.900
Key Statistics
Edit
Prev. Close
0.82
Open
0.71
Day's Range
0.71-0.72
52 wk Range
0.252-8.9
Volume
3.52K
Average Volume (3m)
3.03K
1-Year Change
-88.04%
Book Value / Share
-1.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VCNX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Vaccinex Inc News & Analysis

Show more

Vaccinex Company Profile

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for the treatment of Alzheimer’s disease and has completed phase 2 study for the treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; Pepinemab in combination with Nivolumab completed phase 2 study for melanoma; and trastuzumab and dendritic cell vaccines in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children’s Hospital of Philadelphia; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Compare VCNX to Peers and Sector

Metrics to compare
VCNX
Peers
Sector
Relationship
P/E Ratio
−0.1x−0.6x−0.5x
PEG Ratio
0.000.000.00
Price/Book
−0.5x1.7x2.6x
Price / LTM Sales
3.7x10.8x3.1x
Upside (Analyst Target)
-210.1%51.1%
Fair Value Upside
Unlock20.7%8.9%Unlock

Earnings

Latest Release
Apr 15, 2025
EPS / Forecast
-1.05 / --
Revenue / Forecast
213.00K / --
EPS Revisions
Last 90 days

VCNX Income Statement

FAQ

What Is the Vaccinex (VCNX) Stock Price Today?

The Vaccinex stock price today is 0.71.

What Stock Exchange Does Vaccinex Trade On?

Vaccinex is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Vaccinex?

The stock symbol for Vaccinex is "VCNX."

What Is the Vaccinex Market Cap?

As of today, Vaccinex market cap is 1.90M.

What Is Vaccinex's Earnings Per Share (TTM)?

The Vaccinex EPS (TTM) is -8.88.

From a Technical Analysis Perspective, Is VCNX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Vaccinex Stock Split?

Vaccinex has split 2 times.

How Many Employees Does Vaccinex Have?

Vaccinex has 25 employees.

What is the current trading status of Vaccinex (VCNX)?

As of 16 Jun 2025, Vaccinex (VCNX) is trading at a price of 0.71, with a previous close of 0.82. The stock has fluctuated within a day range of 0.71 to 0.72, while its 52-week range spans from 0.25 to 8.90.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.